Erika Ayers Badan: Women in the Workplace Wake-Up Call
This headline somehow feels both shocking and completely unsurprising. The McKinsey and Lean In Women in the Workplace study is out, and the takeaway is…
Thought Leader: Erika Ayers Badan
Antibodies Can Be the Bridge to a Vaccine
By Luciana Borio and Scott Gottlieb (original source Wall Street Journal)
“America’s coronavirus epidemic has taken a turn for the worse, with many more states showing sharp increases in daily cases compared with two weeks ago. How long will it take for researchers to catch up and develop more effective therapies against Covid-19?
The federal government’s Operation Warp Speed is working with drugmakers to accelerate the development and manufacturing of vaccines. Five candidates are in clinical trials, including one from Pfizer (on whose board one of us, Dr. Gottlieb, sits). More vaccines are expected to enter such trials soon. A safe and effective vaccine is the best hope for ending the pandemic and fully restoring the economy. Everyone is hoping for success—and quickly.
But the path to a vaccine can be long and complex. Enrolling patients in clinical trials, ramping up factories, and producing sufficient supply is an intricate process that can take many months. Distributing vaccines also takes time, and so does encouraging Americans to take them. With so many uncertainties, vaccines aren’t likely to be available widely until next year. That means we need to pursue other potential antidotes.”
Click here to read more
Relevant and recent posts
Dr. Sanjay Gupta: Why Haven’t We Cured the Common Cold?
The average person gets two to four colds a year. With all the missed school and work, that adds up to an economic impact of…
Thought Leader: Sanjay Gupta
Niall Ferguson on the Logic Behind America’s New Worldview
Niall Ferguson argues that the media reaction to President Trump’s new National Security Strategy (NSS) says more about elite assumptions than about the document itself.…
Thought Leader: Niall Ferguson
More with this speaker
Scott Gottlieb on China’s biotech strategy
Thought Leader: Scott Gottlieb
Scott Gottlieb: China’s edge over U.S. biotech
Thought Leader: Scott Gottlieb